Relmada Therapeutics, Inc. (RLMD) Insider Trading Activity

NASDAQ$7.17+2.72 (61.12%)
Market Cap
$326.33M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
90 of 883
Rank in Industry
66 of 506

RLMD Insider Trading Activity

RLMD Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$2,997,466
17
100
Sells
$0
0
0

Related Transactions

Shenouda MagedChief Financial Officer
5
$1.25M
0
$0
$1.25M
TRAVERSA SERGIOChief Executive Officer
8
$1.07M
0
$0
$1.07M
Ence ChuckCA and CO
2
$402,530
0
$0
$402,530
Kelly Paul EdwardChief Operating Officer
2
$284,060
0
$0
$284,060

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Insider Activity of Relmada Therapeutics, Inc.

Over the last 12 months, insiders at Relmada Therapeutics, Inc. have bought $3M and sold $0 worth of Relmada Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Relmada Therapeutics, Inc. have bought $1.11M and sold $987,480 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Shenouda Maged (Chief Financial Officer) — $1.25M. TRAVERSA SERGIO (Chief Executive Officer) — $1.07M. Ence Chuck (CA and CO) — $402,530.

The last purchase of 27,500 shares for transaction amount of $113,300 was made by TRAVERSA SERGIO (Chief Executive Officer) on 2025‑12‑15.

List of Insider Buy and Sell Transactions, Relmada Therapeutics, Inc.

2025-12-15PurchaseTRAVERSA SERGIOChief Executive Officer
27,500
0.0355%
$4.12
$113,300
-5.73%
2025-12-15PurchaseShenouda MagedChief Financial Officer
11,665
0.015%
$4.12
$48,060
-5.73%
2025-11-05PurchaseTRAVERSA SERGIOChief Executive Officer
272,500
0.7992%
$2.20
$599,500
+64.73%
2025-11-05PurchaseShenouda MagedChief Financial Officer
500,000
1.4664%
$2.20
$1.1M
+64.73%
2025-11-05PurchaseKelly Paul EdwardChief Operating Officer
90,000
0.264%
$2.20
$198,000
+64.73%
2025-11-05PurchaseEnce ChuckCAO and COO
136,000
0.3989%
$2.20
$299,200
+64.73%
2025-08-28PurchaseTRAVERSA SERGIOChief Executive Officer
55,976
0.161%
$0.74
$41,422
+398.74%
2025-08-27PurchaseTRAVERSA SERGIOChief Executive Officer
129,455
0.3903%
$0.67
$86,735
+475.13%
2025-08-26PurchaseTRAVERSA SERGIOChief Executive Officer
80,545
0.24%
$0.62
$49,938
+481.76%
2025-05-20PurchaseTRAVERSA SERGIOChief Executive Officer
147,686
0.4151%
$0.56
$82,246
+251.76%
2025-05-20PurchaseShenouda MagedChief Financial Officer
60,000
0.1586%
$0.52
$31,422
+251.76%
2025-05-19PurchaseTRAVERSA SERGIOChief Executive Officer
30,000
0.0888%
$0.50
$14,994
+310.61%
2025-05-19PurchaseShenouda MagedChief Financial Officer
90,000
0.2586%
$0.49
$43,686
+310.61%
2025-05-16PurchaseTRAVERSA SERGIOChief Executive Officer
172,314
0.5063%
$0.45
$77,472
+351.19%
2025-05-16PurchaseKelly Paul EdwardChief Operating Officer
200,000
0.5624%
$0.43
$86,060
+351.19%
2025-05-16PurchaseEnce ChuckCA and CO
228,961
0.6753%
$0.45
$103,330
+351.19%
2025-05-16PurchaseShenouda MagedChief Financial Officer
50,000
0.1444%
$0.44
$22,100
+351.19%
2024-09-11PurchaseTRAVERSA SERGIOChief Executive Officer
51,407
0.1813%
$2.99
$153,707
-19.99%
2024-09-11PurchaseShenouda MagedChief Financial Officer
24,120
0.0839%
$2.95
$71,154
-19.99%
2024-09-10PurchaseTRAVERSA SERGIOChief Executive Officer
33,014
0.1071%
$2.75
$90,789
-14.01%
Total: 105
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
TRAVERSA SERGIOChief Executive Officer
1300000
1.7727%
$5.79M1714
<0.0001%
Shenouda MagedChief Financial Officer
800000
1.0909%
$3.56M1414
<0.0001%
Kelly Paul EdwardChief Operating Officer
502295
0.6849%
$2.24M811
+49.16%
Ence ChuckCAO and COO
403931
0.5508%
$1.8M50
<0.0001%
SETH SANDESHdirector
123258
0.1681%
$548,498.1020
CASAMENTO CHARLES Jdirector
13000
0.0177%
$57,850.00215
<0.0001%
O'Gorman CedricChief Medical Officer
10121
0.0138%
$45,038.4510
+0.32%
Agharkar Shreeramdirector
5759
0.0079%
$25,627.5520
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$26,922,905
100
5.55%
$297.62M
$5,960,789
91
-7.17%
$319.9M
$69,151,774
71
24.96%
$321.71M
$24,384,691
42
-30.27%
$312.43M
$16,169,789
40
7.44%
$332.61M
$64,487,106
32
-22.92%
$311.97M
$54,828,550
26
-13.88%
$340.21M
Relmada Therapeutics, Inc.
(RLMD)
$1,842,003
22
-0.74%
$326.33M
$65,355,913
13
-3.42%
$355.62M
$10,143,329
12
11.84%
$314.35M
$81,667,942
12
-57.54%
$357.88M
$112,952,085
11
-19.19%
$360.3M
$13,043,783
8
732.82%
$305.16M
$603,645
8
57.40%
$360.27M
$1,346,998
7
25.06%
$297.64M
$17,675,244
7
92.20%
$307.8M
$2,720,023
3
-11.76%
$343.41M
$4,888,000
3
-20.50%
$338.6M
$20,020,000
1
-75.24%
$354.71M

RLMD Institutional Investors: Active Positions

Increased Positions57+183.87%43M+560.67%
Decreased Positions9-29.03%217,832-2.81%
New Positions35New34MNew
Sold Out Positions<1Sold Out1,581Sold Out
Total Postitions79+154.84%51M+557.86%

RLMD Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ikarian Capital, Llc$8,054.002.53%1.84M+2M+4,476.76%2025-09-30
Driehaus Capital Management Llc$3,234.001.01%740,00600%2025-09-30
Boothbay Fund Management, Llc$3,029.000.95%693,236+693,236New2025-09-30
Acadian Asset Management Llc$2,546.000.8%582,543-36,936-5.96%2025-09-30
Blackrock, Inc.$2,220.000.7%508,00000%2025-09-30
Vanguard Group Inc$1,829.000.57%418,580+54,503+14.97%2025-09-30
Advisorshares Investments Llc$1,763.000.55%403,488+6,974+1.76%2025-09-30
Geode Capital Management, Llc$1,294.000.41%296,215-6,139-2.03%2025-09-30
Marshall Wace, Llp$1,189.000.37%272,053+117,485+76.01%2025-09-30
Deutsche Bank Ag$983.000.31%224,84600%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.